Table 2.
Treatment response by mRECIST criteria
| All patients | ||||||||
|---|---|---|---|---|---|---|---|---|
| CR | PR | SD | PD | ORR | pv | DCR | pv | |
| Lenvatinib + nivolumab | 7.5% | 37.5% | 37.5% | 17.5% | 45.0% | 0.03 | 83.5% | 0.50 |
| Lenvatinib | 6.4% | 17.0% | 28.7% | 23.4% | 23.4% | 76.6% | ||
| Lenvatinib + nivolumab group | ||||||||
| CR | PR | SD | PD | ORR | pv | DCR | pv | |
| Sorafenib | ||||||||
| Naïve | 15.0% | 40.0% | 30.0% | 15.0% | 55.0% | 0.20 | 85.0% | 0.68 |
| Experienced | 0% | 35.0% | 45.0% | 20.0% | 35.0% | 80.0% | ||
| HBV | ||||||||
| Positive | 6.5% | 41.9% | 35.5% | 16.1% | 48.4% | 0.42 | 83.9% | 0.65 |
| Negative | 11.1% | 22.2% | 44.4% | 22.2% | 33.3% | 77.8% | ||
| HCV | ||||||||
| Positive | 0.0% | 50.0% | 25.0% | 25.0% | 50.0% | 0.83 | 75.0% | 0.68 |
| Negative | 8.3% | 36.1% | 38.9% | 16.7% | 44.4% | 82.5% | ||
| REFLECT criteria | ||||||||
| Fit | 5.3% | 42.1% | 47.4% | 5.3% | 47.4% | 0.78 | 94.7% | 0.10 |
| Unfit | 9.5% | 33.3% | 28.6% | 28.6% | 42.9% | 71.4% | ||
CR complete response, PR partial response, SD stable disease, PD progressive disease, ORR objective response rate, DCR disease-control rate, pv p-value